Скачать или смотреть Assessing Risk of Myelosuppression With PARP Inhibitors in Prostate Cancer With Karan Jatwani, MBBS

Check out the full article here: https://oncdata.com/assessing-risk-of...

At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Dr. Karan Jatwani, third-year Hematology/Oncology Fellow at Roswell Park Comprehensive Cancer Center, sat down to discuss his poster on “Risk Assessment of Myelosuppression with PARP Inhibitors in Prostate Cancer: Insights from FAERS.” This is the first study analyzing the relative rates of myelosuppression events across poly-ADP ribose polymerase (PARP) inhibitors specifically in prostate cancer. In this conversation with Dr. Salman Faisal, Dr. Jatwani elaborates on the research, including:

• Background about the four PARP inhibitors approved for metastatic castration-resistant prostate cancer (CRPC)—olaparib, niraparib, rucaparib, and talazoparib—and their risks of myelosuppressive events
• His team’s study investigating pharmacovigilance, reporting rate, and reaction outcomes of approved PARP inhibitors for metastatic CRPC in US Food and Drug Administration Adverse Event Reporting System (FAERS)
• The incidence of myelosuppressive events, including anemia, leukopenia, thrombocytopenia, pancytopenia, myelodysplastic syndrome, and acute myeloid leukemia, that was found
• Implications for patient selection and vigilant monitoring required to optimize the safety and efficacy of PARP inhibitors in prostate cancer
• And more!